News
Helium Special Situations increases interest in Scancell
17th November 2011Holdings in Company
The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100
Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
XCAP Securities Plc - Broker
Jon Belliss/ Adrian Kirk
+44 (0) 207 101 7070
Press coverage
- What I Learned From the CEO of an Immunotherapy Start-Up
- Biotech blockbusters
- Is this the pioneering DNA vaccine we've been waiting for?
- Electric jab in your arm that fights skin cancer
- Finanz und Wirtschaft 5th June 2013
- Finanz und Wirtschaft 12th June 2013
- ECOreporter 14th August 2013
- Scancell And OncoSec looking good with melanoma immunotherapies
- Why checkpoint inhibitors need help June 2014
Webcasts, Interviews and Media Coverage
Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow
Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.
Fri, 12 May 2017 07:57:00
Scancell Holdings raises £5mln as pace of clinical work quickens
The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.
Thu, 11 May 2017 12:00:00
Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation
Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.
CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.
Wed, 01 Feb 2017 09:53:00